Darunavir/Cob/Emtri/Tenof Alaf
Brand name: Symtuza
Rank #103 of 500 drugs by total cost
$172.5M
Total Cost
34,812
Total Claims
$172.5M
Total Cost
1,037
Prescribers
$4,954
Cost per Claim
1,418
Beneficiaries
35,802
30-Day Fills
$166K
Avg Cost/Provider
34
Avg Claims/Provider
About Darunavir/Cob/Emtri/Tenof Alaf
Darunavir/Cob/Emtri/Tenof Alaf (sold as Symtuza) was prescribed 34,812 times by 1,037 Medicare Part D providers in 2023, costing the program $172.5M. At $4,954 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 100 | Amlodipine Besylate (Amlodipine Besylate) | $180.1M | 20,835,727 |
| 101 | Dolutegravir Sodium/Lamivudine (Dovato) | $173.3M | 56,930 |
| 102 | Potassium Chloride (Klor-Con M20) | $172.6M | 6,137,143 |
| 103 | Darunavir/Cob/Emtri/Tenof Alaf (Symtuza) | $172.5M | 34,812 |
| 104 | Tamsulosin Hcl (Tamsulosin Hcl) | $168.5M | 8,367,036 |
| 105 | Carbidopa/Levodopa (Carbidopa-Levodopa) | $168.3M | 1,361,770 |
| 106 | Duloxetine Hcl (Duloxetine Hcl) | $167.7M | 5,106,690 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology